Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Rating of “Hold” from Analysts

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been assigned an average recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $14.1250.

VNDA has been the topic of a number of research reports. UBS Group reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. B. Riley Financial raised their price target on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, December 31st. Wall Street Zen lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. HC Wainwright increased their target price on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, January 21st.

Vanda Pharmaceuticals Stock Performance

Shares of Vanda Pharmaceuticals stock opened at $8.28 on Thursday. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $9.60. The company has a quick ratio of 2.38, a current ratio of 2.39 and a debt-to-equity ratio of 0.01. The stock has a market cap of $489.43 million, a PE ratio of -2.22 and a beta of 0.62. The business has a fifty day simple moving average of $7.41 and a 200-day simple moving average of $5.83.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The business had revenue of $57.22 million during the quarter, compared to analysts’ expectations of $59.28 million. On average, sell-side analysts anticipate that Vanda Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Stonepine Capital Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 611.3% during the 2nd quarter. Stonepine Capital Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock valued at $1,180,000 after purchasing an additional 214,852 shares in the last quarter. Squarepoint Ops LLC increased its position in Vanda Pharmaceuticals by 96.5% during the second quarter. Squarepoint Ops LLC now owns 153,345 shares of the biopharmaceutical company’s stock worth $724,000 after buying an additional 75,295 shares during the last quarter. R Squared Ltd bought a new position in Vanda Pharmaceuticals during the second quarter valued at about $83,000. Kennedy Capital Management LLC lifted its position in shares of Vanda Pharmaceuticals by 7.7% in the second quarter. Kennedy Capital Management LLC now owns 237,468 shares of the biopharmaceutical company’s stock worth $1,121,000 after buying an additional 17,020 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Vanda Pharmaceuticals by 4.8% in the second quarter. Geode Capital Management LLC now owns 1,691,638 shares of the biopharmaceutical company’s stock worth $7,986,000 after buying an additional 77,997 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.